{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:22:54Z","timestamp":1793064174381,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02819-9","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:49:53Z","timestamp":1766126993000},"page":"440-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8300-1266","authenticated-orcid":false,"given":"Joshua N.","family":"Gustine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Scaringi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0896-5734","authenticated-orcid":false,"given":"Fabian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana D.","family":"Cirstea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9267","authenticated-orcid":false,"given":"Andrew R.","family":"Branagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Puliafito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2819_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"2819_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2819_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2819_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2819_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"2819_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346.","journal-title":"Lancet Oncol"},{"key":"2819_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","volume":"121","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, et al. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819\u201323.","journal-title":"Blood"},{"key":"2819_CR8","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911\u20138.","journal-title":"J Clin Oncol"},{"key":"2819_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of (18)F-FDG-PET\/CT according to deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116\u201325.","journal-title":"J Clin Oncol"},{"key":"2819_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/bloodadvances.2024014360","volume":"9","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Tormo-Ratera M, Oliver-Cald\u00e9s A, Soler-Perromat JC, Gonz\u00e1lez-Calle V, Moreno DF, et al. Clinical impact of [18F]FDG-PET\/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed\/refractory multiple myeloma. Blood Adv. 2025;9:571\u201382.","journal-title":"Blood Adv"},{"key":"2819_CR11","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395.","journal-title":"Blood"},{"key":"2819_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783703","volume":"11","author":"SW Wong","year":"2021","unstructured":"Wong SW, Shah N, Ledergor G, Martin T, Wolf J, Shui AM, et al. Early dynamics and depth of response in multiple myeloma patients treated with BCMA CAR-T cells. Front Oncol. 2021;11:783703.","journal-title":"Front Oncol"},{"key":"2819_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70159","volume":"9","author":"P Born","year":"2025","unstructured":"Born P, Fandrei D, Wang SY, Perez-Fernandez C, Fischer L, Ussmann J, et al. Prognostic significance of PET\/CT for CAR T cell therapy in relapsed\/refractory multiple myeloma. Hemasphere. 2025;9:e70159.","journal-title":"Hemasphere"},{"key":"2819_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","volume":"4","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, et al. Time-dependent prognostic value of serological and measurable residual disease assessments after Idecabtagene vicleucel. Blood Cancer Discov. 2023;4:365\u201373.","journal-title":"Blood Cancer Discov"},{"key":"2819_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00820-y","volume":"13","author":"R Bansal","year":"2023","unstructured":"Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, et al. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023;13:47.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02819-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02819-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02819-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:56:02Z","timestamp":1770274562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02819-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2819"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02819-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MVM is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab and Luminary) and University of Pennsylvania (some licensed to Novartis), receives Grant\/Research support from: Kite Pharma, Moderna, Sobi, holds Equity in 2SeventyBio, A2Bio, Affyimmune, BendBio, Cargo, GBM newco, Model T bio, Neximmune, Oncternal. MVM serves on the board of directors of 2Seventy Bio and is or has been a consultant for A2Bio, Adaptimmune, Affyimmune, BMS, Cabaletta, Cargo, In8bio, GSK, Kite Pharma, Neximmune, Novartis, Oncternal, Sobi. MJF has been a consultant for Novartis, BMS, JnJ\/Legend, Kite\/Gilead, Cytoagents, and SOBI. AJY has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Johnson & Johnson (Janssen), Karyopharm, Oncopeptides, Pfizer, Prothena, Regeneron, Sanofi, Sebia, Takeda, and has received research funding to the institution from Amgen, BMS, GSK, Johnson & Johnson (Janssen), and Sanofi. UM is a co-founder, shareholder, and consultant to CytoSite Biopharma. NSR has been a consultant for AbbVie, Amgen, BMS, Janssen, Pfizer, Immuneel, GSK, K36 Therapeutics, Sanofi, and AstraZeneca, and has received research funding to the institution from Pfizer. The remaining authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}